Are salt loading and prolonging infusion period effective in prevention of amphotericin B-induced nephrotoxicity?

Expert Opinion on Drug Safety

Volumn 11, Issue 6, 2012, Pages 969-983

  Karimzadeh, Iman ^a   Farsaei, Shadi ^a   Khalili, Hossein ^a   Dashti Khavidaki, Simin ^a  

^a TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Amphotericin; Nephrotoxicity; Prevention; Treatment

Indexed keywords

AMPHOTERICIN B; AMPHOTERICIN B CHOLESTEROL SULFATE; AMPHOTERICIN B LIPID COMPLEX; CYCLOSPORIN A; FUROSEMIDE; SODIUM CHLORIDE;

CLINICAL TRIAL; CONTINUOUS INFUSION; CREATININE BLOOD LEVEL; DATA BASE; DRUG INFUSION; GLOMERULUS FILTRATION RATE; GRAFT RECIPIENT; HUMAN; MYCOSIS; NEPHROTOXICITY; NEUTROPENIA; PROPHYLAXIS; REVIEW; RISK FACTOR;

AMPHOTERICIN B; ANIMALS; ANTIFUNGAL AGENTS; CREATININE; GLOMERULAR FILTRATION RATE; HUMANS; INFUSIONS, INTRAVENOUS; KIDNEY DISEASES; KIDNEY FUNCTION TESTS; SODIUM CHLORIDE; TIME FACTORS;

EID: 84867816193     PISSN: 14740338     EISSN: 1744764X     Source Type: Journal    
DOI: 10.1517/14740338.2012.721775     Document Type: Review

References (56)

1. Laniado-Laboŕn R, Cabrales-Vargas MN. Amphotericin B: side effects and toxicity. Rev beroam Micol 2009;26:223-7
2. Ulozas E. Amphotericin B-induced nephrotoxicity. Compr Toxicol 2010;7:347-57
3. Gallis HA, Drew RH, Pickard WW. Amphotericin B: 30 years of clinical experience. Rev Infect Dis 1990;12:308-29
4. Anderson CM. Sodium chloride treatment of amphotericin B nephrotoxicity-standard of care? West J Med 1995;162:313-17
5. Harbarth S, Pestotnik SL, Lloyd JF, et al. The epidemiology of nephrotoxicity associated with conventional amphotericin B therapy. Am J Med 2001;111:528-34
6. Bates DW, Su L, Yu DT, et al. Mortality and costs of acute renal failure associated with amphotericin B therapy. Clin Infect Dis 2001;32:686-93
7. Fanos V, Cataldi L. Amphotericin B-induced nephrotoxicity: a review. J Chemother 2000;12(6):463-70
8. Goldman RD, Koren G. Amphotericin B nephrotoxicity in children. J Pediatr Hematol Oncol 2004;26:421-6
9. Zager RA, Bredl CR, Schimpf BA. Direct amphotericin B-mediated tubular toxicity: assessments of selected cytoprotective agents. Kidney Int 1992;41:1588-94
10. Zietse R, Zoutendijk R, Hoorn EJ. Fluid, electrolyte and acid-base disorders associated with antibiotic therapy. Nat Rev Nephrol 2009;5:193-202
11. Bagnis CI, Deray G. Amphotericin B nephrotoxicity. Saudi J Kidney Dis Transplant 2002;13:481-91
12. Wingard JR, Kubilis P, Lee L, et al. Clinical significance of nephrotoxicity in patients treated with amphotericin B for suspected or proven aspergillosis. Clin Infect Dis 1999;29:1402-7
13. Feely J, Heidemann H, Gerkens J, et al. Sodium depletion enhances nephrotoxicity of amphotericin B. Lancet 1981;1:1422-3
14. Heidemann HT, Gerkens JF, Spickard WA, et al. Amphotericin B nephrotoxicity in humans decreased by salt repletion. Am J Med 1983; 75:476-81
15. Branch RA, Jackson EK, Jacqz E, et al. Amphotericin-B nephrotoxicity in humans decreased by sodium supplements with coadministration of ticarcillin or intravenous saline. Klin Wochenschr 1987;65:500-6
16. Stein RS, Albridge K, Lenox RK, et al. Nephrotoxicity in leukemic patients receiving empirical amphotericin B and aminoglycosides. South Med J 1988;81:1095-9
17. Arning M, Scharf R. Prevention of amphotericin-B-induced nephrotoxicity by loading with sodium chloride: a report of 1291 days of treatment with amphotericin B without renal failure. Klin Wochenschr 1989;67:1020-8
18. Stein RS, Alexander JA. Sodium protects against nephrotoxicity in patients receiving amphotericin B. Am J Med Sci 1989;298:299-304
19. Llanos A, Cieza J, Bernardo J, et al. Effect of salt supplementation on amphotericin B nephrotoxicity. Kidney Int 1991;40:302-8
20. Mayer J DM, Doubek J, Horký D, et al. Reduced nephrotoxicity of conventional amphotericin B therapy after minimal nephroprotective measures: animal experiments and clinical study. J Infect Dis 2002;186:379-88
21. Girmenia C, Cimino G, Cristofano F, et al. Effects of hydration with salt repletion on renal toxicity of conventional amphotericin B empirical therapy: a prospective study in patients with hematological malignancies. Support Care Cancer 2005;13:987-92
22. Berdichevski RH, Luis LB, Crestana L, et al. Amphotericin B-related nephrotoxicity in low-risk patients. BJID 2006;10:94-9
23. Richardson DK, Gray JE, Gortmaker SL, et al. Declining severity adjusted mortality: evidence of improving neonatal intensive care. Pediatrics 1998;102:893-9
24. Stoll BJ, Hansen N, Fanaroff AA, et al. Late-onset sepsis in very low birth weight neonates: the experience of the NICHD Neonatal Research Network. Pediatrics 2002;110:285-91
25. Friedman S, Richardson SE, Jacobs SE, O'Brien K. Systemic Candida infection in extremely low birth weight infants: short term morbidity and long term neurodevelopmental outcome. Pediatr Infect Dis J 2000;19:499-504
26. Holler B, Omar SA, Farid MD, et al. Effects of fluid and electrolyte management on amphotericin B-induced nephrotoxicity among extremely low birth weight infants. Pediatrics 2004;113:e608-16
27. Turcu R, Patterson MJ, Omar S. Influence of sodium intake on Amphotericin B-induced nephrotoxicity among extremely premature infants. Pediatr Nephrol 2009;24:497-505
28. Echevarria J, Seas C, Cruz M, et al. Oral rehydration solution to prevent nephrotoxicity of amphotericin B. Am J Trop Med Hyg 2006;75:1108-12
29. Slain D. Lipid-based amphotericin B for the treatment of fungal infections. Pharmacotherapy 1999;19:306-23
30. White MH, Bowden RA, Sandler ES, et al. Randomized, double-blind clinical trial of amphotericin B colloidal dispersion vs. amphotericin B in the empirical treatment of fever and neutropenia. Clin Infect Dis 1998; 27:296-302
31. Costa S, Nucci M. Can we decrease amphotericin nephrotoxicity? Curr Opin Crit Care 2001;7:379-83
32. Macauly SS, Martin JE, Zarnke KB. Amphotericin B for the treatment of systemic fungal infections: meta-analysis of conventional versus lipid formulations [abstract M-888]. Interscience Conference on Antimicrobial Agents and Chemotherapy; 2002
33. Barrett JP, Vardulaki KA, Conlon C, et al. A systematic review of the antifungal effectiveness and tolerability of amphotericin B formulations. Clin Ther 2003;25:1295-320
34. Mehta R, Lopez-Berestein G, Hopfer R, et al. Liposomal amphotericin B is toxic to fungal cells but not to mammalian cells. Biochim Biophys Acta 1984;770:230-4
35. Proffitt RT, Satorius A, Chiang SM et al. Pharmacology and toxicology of a liposomal formulation of amphotericin B (AmBisome) in rodents. J Antimicrob Chemother 1991;28(Suppl B):49-61
36. Lee JW, Amantea MA, Francis PA, et al. Pharmacokinetics and safety of a unilamellar liposomal formulation of amphotericin B (AmBisome) in rabbits. Antimicrob Agents Chemother 1994;38:713-18
37. Wasan KM, Rosenblum MG, Cheung L, et al. Influence of lipoproteins on renal cytotoxicity and antifungal activity of amphotericin B. Antimicrob Agents Chemother 1994;38:223-7
38. Perkins WR, Minchey SR, Boni LT, et al. Amphotericin B-phospholipid interactions responsible for reduced mammalian cell toxicity. Biochim Biophys Acta 1992;1107:271-82
39. Ellis ME, al-Hokail AA, Clink HM, et al. Double-blind randomized study of the effect of infusion rates on toxicity of amphotericin B. Antimicrob Agents Chemother 1992;36:172-9
40. Cruz JM, Peacock JE Jr, Loomer L, et al. Rapid intravenous infusion of amphotericin B: a pilot study. Am J Med 1992;93:123-30
41. Eriksson U, Seifert B, Schaffner A. Comparison of effects of amphotericin B deoxycholate infused over 4 or 24 hours: randomized controlled trial. BMJ 2001;322:1-6
42. Imhof A, Walter RB, Schaffner A. Continuous infusion of escalated doses of amphotericin B deoxycholate: an open-label observational study. CID 2003;36:943-51
43. Peleg A, Woods M. Continuous and 4 h infusion of amphotericin B: a comparative study involving high-risk haematology patients. JAC 2004;54:803-8
44. Uehara RP SV, Koshimura ET, Prudente FV, et al. Continuous infusion of amphotericin B: preliminary experience at Faculdade de Medicina da Fundacao ABC. Sao Paulo Med J 2005;123:219-22
45. Walsh TJ, Finberg RW, Arndt C, et al. Liposomal amphotericin B for empirical therapy in patients with persistent fever and neutropenia. N Engl J Med 1999;340:764-71
46. Schulenburg A SW, Rabitsch W, Knaobl P, et al. Brief report: practicability and safety of amphotericin B deoxycholate as continuous infusion in neutropenic patients with hematological malignancies. Leuk Lymphoma 2005;46:1163-7
47. Maharom P, Thamlikitkul V. Implementation of Clinical Practice Policy on the Continuous Intravenous Administration of Amphotericin B Deoxycholate. J Med Assoc Thai 2006;89:S118-24
48. Altmannsberger P, Holler E, Andreesen R, et al. Amphotericin B deoxycholate: no significant advantage of a 24 h over a 6 h infusion schedule. J Antimicrob Chemother 2007;60:180-2
49. Speich R, Dutly A, Naef R, et al. Tolerability, safety and efficacy of conventional amphotericin B administered by 24-hour infusion to lung transplant recipients. SWISS MED WKLY 2002;132:455-8
50. Furrer K, Schaffner A, Vavricka SR, et al. Nephrotoxicity of cyclosporine A and amphotericin B-deoxycholate as continuous infusion in allogeneic stem cell transplantation. SWISS MED WKLY 2002;132:316-20
51. Trissel L. Handbook on injectable drugs. 16th edition. American society of health-system pharmacists; 7272, Wisconsin Avenue, Bethesda MD 20814. 2011
52. Gallelli JF. Assay and stability of amphotericin B in aqueous solutions. Ann Pharmacother 1967;1:102-5
53. Block ER, Bennett JE. Stability of amphotericin B in infusion bottles. Antimicrob Agents Chemother 1973;4:648-9
54. Shadomy S, Brummer DL, Ingroff AV. Light sensitivity of prepared solutions of amphotericin B. Am Rev Respir Dis 1973;107:303-4
55. Klepser ME, Wolfe EJ, Jones RN, et al. Antifungal pharmacodynamic characteristics of fluconazole and amphotericin B tested against Candida albicans. Antimicrob Agents Chemother 1997;41:1392-5
56. Klepser ME, Wolfe EJ, Pfaller MA. Antifungal pharmaco-dynamic characteristics of fluconazole and amphotericin B against Cryptococcus neoformans. J Antimicrob Chemother 1998;41:397-401